Anti-COVID-2019 antibody therapeutic - Agency for Science, Technology and Research/Chugai Pharmabody Research
Latest Information Update: 28 Jun 2024
At a glance
- Originator Agency for Science, Technology and Research; Chugai Pharmabody Research
- Class Antibodies; Antivirals
- Mechanism of Action Virus internalisation inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported COVID 2019 infections
Most Recent Events
- 28 Jun 2024 No recent reports of development identified for research development in COVID-2019-infections in Singapore (Parenteral)
- 15 May 2020 Eli Lilly and Company in-licenses antibody engineering technologies from Chugai Pharmaceutical for the development of the antibody therapeutics against COVID-2019 infection
- 08 May 2020 Chugai Pharmabody Research enters into a collaborative agreement with Agency for Science, Technology and Research (A*STAR) for development of an antibody therapeutic for COVID-2019 injections (Parenteral)